BACTERIOPHAGE THERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Bacteriophage therapy has played a significant role in research fields of molecular biology and biotechnology since a long time. Phage-based treatment therapy is expected to emerge as a new treatment for managing persistent bacterial infections. These factors are widening the potential scope for drug discovery. Increasing prevalence of drug-resistant infections is also expected to drive demand for bacteriophage therapy to help in overcoming an infection outbreak. For instance, as per the Centers for Disease Control and Prevention (CDC), in February 2019, around 129 people from 32 U.S. states were infected with the outbreak of strain Salmonella Infantis infection. Moreover, the CDC had conducted an antibiotic resistance testing on Salmonella bacteria isolated from infected patients, which showed that the outbreak strain was resistant to multiple antibiotics.

Increasing research and development of products is expected to propel the market growth. For instance, in September 2019, Armata Pharamceutical Inc. developed a new synthetic phage candidate targeting pathogen Pseudomonas aeruginosa for treatment of serious respiratory infections, with an emphasis on cystic fibrosis patients.

Market Dynamics

Increasing incidences of antibiotic resistance, rising adoption of inorganic growth strategies by key players, and increasing launches and approval of novel products is expected to drive the growth of global bacteriophage therapy market over the forecast period.

For instance, in February 2019, the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy. The application for the clinical study was submitted by physician-scientists at the University Of California San Diego School Of Medicine. Following the U.S. FDA approval, the company plans to initiate phase I/II clinical trial study to test AB-SA01, an experimental bacteriophage combination for the treatment of participants with ventricular assist devices (VADs) infected by resistant Staphylococcus aureus (S. aureus).

Key features of the study:

• This report provides in-depth analysis of the global bacteriophage therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2030), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bacteriophage therapy market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux, Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Enbiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, ContraFect Corporation, and OPTIPHARM Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global bacteriophage therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bacteriophage therapy market.

Detailed Segmentation:

• Global Bacteriophage Therapy Market, By Targeted Bacteria:
• Escherichia coli
• Staphylococcus Aureus
• Streptococcus
• Pseudomonas aeruginosa
• Salmonella
• Others
• Global Bacteriophage Therapy Market, By Disease Indication:
• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
• Global Bacteriophage Therapy Market, By Route of Administration:
• Oral
• Topical
• Parenteral
• Global Bacteriophage Therapy Market, By Region:
• North America
• By Targeted Bacteria
• Escherichia coli
• Staphylococcus aureus
• Streptococcus
• Pseudomonas aeruginosa
• Salmonella
• Others
• By Disease Indication
• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
• Route of Administration
• Oral
• Topical
• Parenteral
• By Country
• U.S.
• Canada
• Latin America
• By Targeted Bacteria
• Escherichia coli
• Staphylococcus aureus
• Streptococcus
• Pseudomonas aeruginosa
• Salmonella
• Others
• By Disease Indication
• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
• Route of Administration
• Oral
• Topical
• Parenteral
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Targeted Bacteria
• Escherichia coli
• Staphylococcus aureus
• Streptococcus
• Pseudomonas aeruginosa
• Salmonella
• Others
• By Disease Indication
• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
• Route of Administration
• Oral
• Topical
• Parenteral
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Targeted Bacteria
• Escherichia coli
• Staphylococcus aureus
• Streptococcus
• Pseudomonas aeruginosa
• Salmonella
• Others
• By Disease Indication
• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
• Route of Administration
• Oral
• Topical
• Parenteral
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Targeted Bacteria
• Escherichia coli
• Staphylococcus aureus
• Streptococcus
• Pseudomonas aeruginosa
• Salmonella
• Others
• By Disease Indication
• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
• Route of Administration
• Oral
• Topical
• Parenteral
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Targeted Bacteria
• Escherichia coli
• Staphylococcus aureus
• Streptococcus
• Pseudomonas aeruginosa
• Salmonella
• Others
• By Disease Indication
• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Others (Eye Infections, Lung Infections, Oral Infections, GI Infections, etc.)
• Route of Administration
• Oral
• Topical
• Parenteral
• By Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Armata Pharmaceuticals, Inc.*
• Company Overview
• Material Portfolio
• Financial Performance
• Key Highlights
• Market Strategies
• Eliava Biopreparations Ltd.
• Pherecydes Pharma
• Intralytix, Inc.
• Phagelux, Inc.
• Nextbiotics
• InnoPhage, Ltd
• Locus Biosciences, Inc.
• TechnoPhage
• Eligo Bioscience SA
• Phagomed Biopharma GmbH.
• PhagePro, Inc.
• Adaptive Phage Therapeutics.
• Enbiotix, Inc.
• Intodeworld, Inc.
• BiomX Ltd.
• Phi Therapeutics
• Fixed-phage Ltd.
• Micreos BV
• ContraFect Corporation
• OPTIPHARM Co., Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.